Research
Cancer Treatment and Hot Flashes: Tamoxifen and Aromatase Inhibitors
Hot flashes and night sweats (together called vasomotor symptoms) are among the most common side effects of endocrine therapy for hormone-receptor-positive breast cancer. In a cohort of 864 women on tamoxifen from the Women's Healthy Eating and Living trial, 78% reported hot flashes. In head-to-head randomized trials of aromatase inhibitors, rates were broadly similar or slightly lower: about 35.7% on anastrozole vs 40.9% on tamoxifen (ATAC), and 33.5% on letrozole vs 38% on tamoxifen (BIG 1-98). Symptoms can be intense enough to affect treatment adherence, and non-hormonal options such as venlafaxine can reduce them (about a 61% drop in hot flash scores in one randomized trial versus 27% on placebo). This page compiles the verified figures. It is educational, not medical advice; endocrine therapy decisions belong with an oncologist.
By the Sweat Explained Editorial Team · Published 2026-07-19 · Last reviewed 2026-07-19 · Educational information, not medical advice.
Key statistics at a glance
78%
of women taking tamoxifen for early breast cancer reported hot flashes in a large US cohort (n=864)
Mortimer 2008 (WHEL)
up to 80%
of women on tamoxifen experience hot flashes; approximately 30% rate them as severe
Reviews (e.g., Sestak 2009)
40.9% vs 35.7%
incidence of hot flashes in the ATAC trial, tamoxifen vs anastrozole
ATAC trial (Buzdar 2006)
38% vs 33.5%
incidence of hot flashes in the BIG 1-98 trial, tamoxifen vs letrozole
BIG 1-98 (Coates 2007)
61% vs 27%
reduction in hot flash score on venlafaxine 75 mg/day vs placebo (4-week randomized trial)
Loprinzi 2000
≈80%
of men on androgen deprivation therapy for prostate cancer experience hot flashes
Vitolins 2013; ONS guideline
Why cancer treatments trigger hot flashes
Hot flashes originate in the brain, at the hypothalamus, when the body's thermoregulatory 'set point' becomes unstable in the setting of low or fluctuating sex-steroid signaling. In natural menopause, that instability is driven by falling estrogen. In cancer care, several treatments produce a similar effect. Selective estrogen receptor modulators like tamoxifen block estrogen signaling in some tissues, including the brain. Aromatase inhibitors (anastrozole, letrozole, exemestane) lower circulating estrogen by blocking its synthesis from androgens in postmenopausal women. Chemotherapy can induce menopause abruptly by damaging the ovaries. And in prostate cancer, androgen deprivation therapy lowers testosterone and, downstream, estradiol, producing hot flashes through a related mechanism in men.
The result is that hot flashes are among the most common and bothersome side effects of endocrine cancer therapy. They can be frequent, drenching, and disruptive to sleep, and are associated with lower adherence to the very treatments that reduce cancer recurrence. That makes measuring and managing them clinically important.
How often tamoxifen causes hot flashes in practice
Rates reported in observational cohorts of women actually on tamoxifen are typically higher than in prevention or randomized trials, in part because women who cannot tolerate side effects drop out of trials. The chart shows two frequently cited real-world figures alongside the higher end of the review literature.
| Group | Value |
|---|---|
| WHEL cohort on tamoxifen (n=864) | 78% (Mortimer 2008; 69% of those with hot flashes also had night sweats) |
| UK cohort on tamoxifen (n=531) | 84% (Fenlon 2017; 60% rated symptoms severe) |
| Upper bound in review literature | 80% ('up to 80%'; ~30% rate hot flashes as severe) |
Source: Mortimer 2008 (WHEL); Fenlon 2017; reviews (e.g., Sestak 2009). Chart is an original rendering of the cited data.
Head-to-head trials: tamoxifen vs aromatase inhibitors
Randomized trials of adjuvant endocrine therapy record hot flashes as a pre-specified adverse event. Rates are consistently in the 33-42% range in these settings and modestly differ between agents. Both classes cause hot flashes; the pattern of other side effects (arthralgia, vaginal discharge, thromboembolism, endometrial cancer) differs more.
| Trial | Comparison | Tamoxifen | Aromatase inhibitor | P value |
|---|---|---|---|---|
| ATAC (n=6,186) | Anastrozole vs tamoxifen | 40.9% | 35.7% | <0.0001 |
| BIG 1-98 (n=4,895) | Letrozole vs tamoxifen | 38% | 33.5% | 0.001 |
| IES (n=4,742) | Exemestane after 2-3 yrs tamoxifen | 39.6% | 42% | 0.082 |
These trials enrolled postmenopausal women with hormone-receptor-positive early breast cancer. Rates reflect the specific populations and reporting methods in each trial and are not directly comparable across trials.
Why real-world rates run higher than trial rates
The 78-84% figures from observational cohorts and the 33-41% figures from adjuvant trials look inconsistent but are not. Three factors explain most of the gap. First, the trials count hot flashes as an adverse event only when actively reported and often only if they are new or worsened; cohorts count every woman reporting hot flashes. Second, trial populations tend to exclude women with the most severe baseline symptoms, and women who cannot tolerate the drug in the trial often discontinue and drop out of adverse-event tallies. Third, adjuvant trials enroll postmenopausal women (many of whom already have hot flashes at baseline), which can compress the 'new hot flash' rate.
For patients and clinicians, the practical implication is that a much higher fraction of women on tamoxifen will report some hot flashes than the trial percentages might suggest, but the direction of the drug effect (more hot flashes on tamoxifen than on placebo, and roughly similar or slightly less with aromatase inhibitors) is well supported.
Hot flashes and adherence to endocrine therapy
Because 5-10 years of endocrine therapy meaningfully reduces breast cancer recurrence, poor adherence has real oncologic consequences. Hot flashes and night sweats consistently rank among the most common reasons women stop or switch endocrine therapy.
- In observational studies of women on tamoxifen or aromatase inhibitors, tamoxifen-associated symptoms have been reported to result in discontinuation in more than 40% of women in some series (Sestak 2009 and related reviews).
- Persistence of hot flashes is common: in one UK cohort of 531 women on tamoxifen, symptoms often persisted through 5 years of treatment, and about 60% of women with hot flashes or night sweats rated them as severe.
- In the WHEL analysis, women who reported hot flashes at baseline had significantly lower subsequent breast cancer recurrence (12.9% vs 21% at 7.3 years, p=0.01), an association hypothesized to reflect greater estrogen suppression on tamoxifen, though this is an observational finding and not a treatment recommendation.
Managing hot flashes when hormone therapy is off the table
For women with a history of breast cancer, estrogen-based menopausal hormone therapy is generally avoided. Multiple randomized trials have therefore evaluated non-hormonal treatments. The best-known is a 2000 Lancet trial by Loprinzi and colleagues that tested venlafaxine, a serotonin-norepinephrine reuptake inhibitor. In 191 women with a history of breast cancer (or reluctance to use hormones), median hot flash scores fell from baseline by 27% on placebo, 37% on 37.5 mg/day, 61% on 75 mg/day, and 61% on 150 mg/day, with more side effects (dry mouth, nausea, decreased appetite) at the higher doses. The authors recommended 75 mg/day as a practical dose.
Other non-hormonal options with randomized-trial support include some SSRIs (paroxetine, escitalopram), gabapentin, oxybutynin, and the neurokinin-3 receptor antagonist fezolinetant, which the FDA approved in 2023 for moderate-to-severe vasomotor symptoms in menopause (though its use in breast cancer survivors is off-label and less studied). A separate research page covers the non-hormonal evidence in detail. Because certain SSRIs (notably paroxetine and fluoxetine) inhibit CYP2D6 and may reduce activation of tamoxifen, drug interactions matter and choices should be individualized with an oncologist.
A note on prostate cancer and androgen deprivation therapy
Hot flashes are not limited to breast cancer therapy. About 80% of men on androgen deprivation therapy for prostate cancer (surgical or medical castration, or GnRH agonists such as leuprolide) experience hot flashes, which can persist for years, and roughly a quarter describe them as their most bothersome side effect. The mechanism is analogous: rapid suppression of sex-steroid signaling destabilizes hypothalamic thermoregulation. Non-hormonal management strategies (venlafaxine and other SNRIs, gabapentin, clonidine) have been studied in men as well, with generally modest but real reductions in hot flash frequency.
How to read these numbers
Three cautions keep the figures in proportion. First, hot flash rates depend heavily on how they are measured (self-report versus adverse-event reporting, any severity versus moderate/severe, at one time point versus over time), which is the main reason the same drug shows a 40% rate in one dataset and 78% in another. Second, trials of endocrine therapy in early breast cancer used specific populations (postmenopausal women, hormone-receptor-positive tumors) and may not generalize to premenopausal women, ovarian suppression regimens, or metastatic disease. Third, the venlafaxine trial data are strong but short (4 weeks), and long-term efficacy and safety in cancer survivors are less thoroughly characterized.
What the evidence supports is directional and well documented: hot flashes are a common, sometimes severe, side effect of both tamoxifen and aromatase inhibitors; head-to-head rates in adjuvant trials are broadly similar, with anastrozole and letrozole showing modestly lower rates than tamoxifen; symptoms can affect treatment adherence; and effective non-hormonal options exist. Anyone considering starting, switching, or stopping endocrine therapy should discuss it with their oncologist. This page is educational; it is not medical advice and not a basis for changing treatment.
Methodology and limitations
This page draws on primary trial and cohort publications: the ATAC completed-treatment analysis (Buzdar 2006 / Howell 2005) for anastrozole versus tamoxifen; the BIG 1-98 trial (Coates 2007) for letrozole versus tamoxifen; the Intergroup Exemestane Study (Coombes 2004) for exemestane switch after tamoxifen; the Women's Healthy Eating and Living cohort analysis (Mortimer 2008) for real-world tamoxifen hot flash prevalence; a UK observational study of tamoxifen menopausal symptoms (Fenlon 2017); the Loprinzi (2000) Lancet randomized trial of venlafaxine for hot flashes in breast cancer survivors; and the Oncology Nursing Society hot flash guideline (Kaplan 2020) plus a peer-reviewed review of ADT-related hot flashes for prostate cancer context. Every figure was traced to its source and confirmed.
Limitations: trial adverse-event rates depend on reporting methods and populations and are not directly comparable across trials; adjuvant trials enrolled specific populations (typically postmenopausal, hormone-receptor-positive early breast cancer) and results may not generalize to all patients or settings; the venlafaxine RCT was 4 weeks long; and observational cohort figures are subject to selection and recall biases. Nothing here is medical advice; endocrine therapy decisions belong with an oncologist.
Frequently asked questions
- How often does tamoxifen cause hot flashes?
- Frequently. In a real-world cohort of 864 women on tamoxifen (WHEL), 78% reported hot flashes; a UK cohort found 84% experienced hot flashes and 80% night sweats. Randomized trials record lower rates (about 38-41%), largely because trial reporting captures only new or worsened symptoms and excludes women who drop out.
- Are hot flashes worse on tamoxifen or aromatase inhibitors?
- Head-to-head trials suggest they are broadly similar, with modestly higher rates on tamoxifen: 40.9% on tamoxifen vs 35.7% on anastrozole (ATAC), 38% on tamoxifen vs 33.5% on letrozole (BIG 1-98), and 39.6% on tamoxifen vs 42% on exemestane (IES). The main safety differences between classes are joint symptoms, vaginal effects, and clot or endometrial risk, not hot flashes.
- Why do observational studies show 78-84% and trials show 33-41%?
- Because they measure different things. Trials count hot flashes as a reported adverse event and often only when new or worsened, and women intolerant of side effects tend to leave the trial. Observational cohorts count every woman who says she has hot flashes at any time. Both are correct for their own question.
- What non-hormonal treatments have evidence for cancer-related hot flashes?
- Venlafaxine has the best-established evidence: in a randomized trial, 75 mg/day reduced hot flash scores by 61%, versus 27% on placebo, over 4 weeks. Other options with randomized-trial support include some SSRIs (paroxetine, escitalopram), gabapentin, and oxybutynin. Some SSRIs may reduce activation of tamoxifen via CYP2D6, so drug choice should be individualized with an oncologist.
- Do hot flashes on tamoxifen mean the drug is working?
- An observational analysis of the WHEL cohort found that women who reported hot flashes at baseline had a lower rate of recurrence at 7.3 years (12.9% vs 21%, p=0.01), consistent with the hypothesis that hot flashes may reflect greater estrogen suppression. This is an association, not a treatment recommendation, and does not mean women without hot flashes are receiving less benefit.
- What about men on prostate cancer treatment?
- About 80% of men on androgen deprivation therapy for prostate cancer experience hot flashes, and roughly a quarter consider them their most bothersome side effect. Non-hormonal options studied in men include venlafaxine and other SNRIs, gabapentin, and clonidine, with modest but real reductions in symptom scores in randomized trials.
Sources
Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).
- Mortimer JE, Flatt SW, Parker BA, et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008;108(3):421-426. 864 women on tamoxifen in the WHEL trial; 78% reported hot flashes. Full text (PMC2575100)
- Buzdar AU, Howell A, Cuzick J, et al. (ATAC Trialists' Group). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-643. Hot flashes 35.7% anastrozole vs 40.9% tamoxifen (P<0.0001). PubMed
- Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486-492. Hot flashes 33.5% letrozole vs 38% tamoxifen (P=0.001). PubMed
- Coombes RC, Hall E, Gibson LJ, et al. (Intergroup Exemestane Study). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-1092. Hot flashes 42% exemestane vs 39.6% tamoxifen (P=0.082). PubMed
- Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059-2063. Hot flash score reductions: placebo 27%, venlafaxine 75 mg/day 61%. PubMed
- Fenlon D, Powers C, Simmonds P, Clough J, Addington-Hall J. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. J Adv Nurs. 2017;73(6):1416-1428. 84% hot flushes; 80% night sweats; 60% severe. (secondary) Full text
- Kaplan M, Ginex PK, Michaud LB, et al. ONS Guidelines for Cancer Treatment-Related Hot Flashes in Women with Breast Cancer and Men with Prostate Cancer. Oncol Nurs Forum. 2020;47(4):374-399. Notes ~80% hot flash prevalence on ADT for prostate cancer. (secondary) ONS PDF
How to cite this page
Sweat Explained. Cancer Treatment and Hot Flashes: Tamoxifen and Aromatase Inhibitors. Published 2026-07-19; last reviewed 2026-07-19. Available at: https://sweatexplained.com/research/cancer-treatment-hot-flashes
Please cite the original studies for the underlying figures. Journalists are welcome to link to this page; the charts are original renderings of the cited data.